argenex SE (NASDAQ:ARGX – Free Report) – Equities researchers at HC Wainwright upped their Q2 2026 earnings estimates for argenex in a research report issued on Friday, May 8th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $5.35 for the quarter, up from their prior estimate of $4.06. HC Wainwright currently has a “Buy” rating and a $940.00 price objective on the stock. The consensus estimate for argenex’s current full-year earnings is $23.96 per share. HC Wainwright also issued estimates for argenex’s Q3 2026 earnings at $6.48 EPS, FY2026 earnings at $24.35 EPS, FY2027 earnings at $29.89 EPS, FY2028 earnings at $38.06 EPS, FY2029 earnings at $46.45 EPS and FY2030 earnings at $55.51 EPS.
argenex (NASDAQ:ARGX – Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The company had revenue of $1.31 billion during the quarter.
Read Our Latest Stock Analysis on ARGX
argenex Trading Up 4.0%
NASDAQ:ARGX opened at $813.28 on Tuesday. argenex has a 12 month low of $510.05 and a 12 month high of $934.62. The company has a market cap of $50.58 billion, a PE ratio of 36.21, a price-to-earnings-growth ratio of 1.31 and a beta of 0.46. The company has a 50 day simple moving average of $755.99 and a two-hundred day simple moving average of $816.91.
Institutional Trading of argenex
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Abound Wealth Management grew its stake in argenex by 3,200.0% in the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after acquiring an additional 32 shares in the last quarter. Sound Income Strategies LLC bought a new position in argenex in the 4th quarter worth about $28,000. Whipplewood Advisors LLC bought a new position in argenex in the 1st quarter worth about $28,000. Ameriflex Group Inc. bought a new position in argenex in the 3rd quarter worth about $32,000. Finally, Sunbelt Securities Inc. bought a new position in argenex in the 3rd quarter worth about $36,000. 60.32% of the stock is owned by hedge funds and other institutional investors.
argenex Company Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
See Also
- Five stocks we like better than argenex
- TMC Forges a New EV Supply Chain at the Bottom of the Sea
- Sell in May and Go Away—Starting With These 3 Stocks
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
